Jakarta, March 27, 2025. Based on the Consolidated Financial Statements of PT Enseval Putera Megatrading Tbk and its Subsidiaries (the Company) as of December 31, 2024, and for the period then ended (Audited), the Company hereby informs that at the end of 2024, the Company's Net Sales were recorded at Rp30,957.34 billion, representing an 8.59% increase compared to the Rp28,507.87 billion recorded at the end of 2023.

The Company's Cost of Goods Sold at the end of 2024 was recorded at Rp27,885.42 billion, an 8.95% increase compared to the Rp25,594.51 billion recorded at the end of 2023.

Thus, the Company recorded a Gross Profit of IDR 3,071.92 billion at the end of 2024, a 5.44% increase compared to the Gross Profit of IDR 2,913.36 billion at the end of 2023.

At the end of 2024, the Company's Operating Expenses were recorded at IDR 2,107.87 billion, consisting of Selling Expenses of IDR 1,852.58 billion and General and Administrative Expenses of IDR 255.29 billion, representing a 3.40% increase compared to the end of 2023. Consequently, the Company recorded an Operating Profit of IDR 964.05 billion, a 10.21% increase compared to the Operating Profit of IDR 874.76 billion at the end of 2023.

The Company's Profit Before Income Tax Expense at the end of 2024 was recorded at IDR 956.59 billion, an increase of 7.65% compared to the same period in 2023. Other Income (Expenses) consisted of finance income of IDR 18.28 billion, finance expenses of IDR 23.66 billion, final tax expense of IDR 5.01 billion, net profit share in associates of IDR 7.95 billion, other operating income of IDR 25.71 billion, and other operating expenses of IDR 30.74 billion.

The Company's Income Tax Expense at the end of 2024 was recorded at IDR 218.26 billion, an increase of 9.02% compared to the same period in 2023, which was IDR 200.20 billion.

As a result, the Company recorded a Profit for the Year of Rp738.33 billion at the end of 2024, a 7.26% increase compared to Rp688.37 billion for the same period in 2023.

Comparing the Company's Consolidated Statement of Financial Position as of December 31, 2024 (Audited) with the Company's Consolidated Statement of Financial Position as of December 31, 2023 (Audited), the Company's Total Assets increased by 4.85%, from Rp10.96 trillion to Rp11.49 trillion. The Company's Total Liabilities increased by 6.88%, from Rp3.66 trillion to Rp3.91 trillion. Consequently, the Company's Total Equity increased by 3.83%, from Rp7.30 trillion to Rp7.58 trillion.

Performance of Each Division

The Company currently has seven divisions, consisting of Consumer Goods, Prescription Drugs, Over-the-Counter Drugs, Raw Materials for Sale, Medical Equipment, Veterinary and Livestock Drugs, and Healthcare and Transportation Services.

The details of the performance of each division within the Company are as follows:

• The Consumer Goods Division contributed the largest to total Net Sales, accounting for 39.40%. At the end of 2024, this division recorded Net Sales of IDR 12,197.40 billion, an increase of 2.79% compared to the same period in 2023.
• The Prescription Drugs Division contributed the second-largest revenue after the Consumer Goods Division, accounting for 33.78%. By the end of 2024, the Prescription Drugs Division recorded Net Sales of Rp10,456.68 billion, representing a 13.73% increase compared to the same period in 2023.
• The Over-the-Counter Drugs Division recorded Net Sales of Rp4,145.21 billion at the end of 2024, contributing 13.39% of the total revenue, a 16.49% increase compared to the same period in 2023.
• The Raw Materials for Sale Division recorded Net Sales of Rp2,390.95 billion at the end of 2024, a 6.87% increase compared to the same period in 2023, and contributing 7.72%.
• The Medical Devices Division contributed 5.30% of the Company's revenue at the end of 2024, with Net Sales of Rp1,640.64 billion, an 8.93% increase compared to the same period in 2023.
• Net Sales from the Animal and Livestock Medicine Division were recorded at Rp53.73 billion, an increase of 4.90% compared to the same period in 2023. The Animal and Livestock Medicine Division contributed 0.17% to the Company's total Net Sales.
• Net Sales from the Healthcare Services and Transportation Division were recorded at Rp72.74 billion, a 21.97% decrease compared to the same period in 2023. This division contributed 0.23%.

About Enseval

Enseval is Indonesia's largest distribution company, having been operating since 1973 and employing over 4,600 people. Enseval went public on August 1, 1994, under the name PT Enseval Putera Megatrading Tbk (IDX: EPMT). In addition to distributing Kalbe Group products, Enseval is also trusted by other principals, both domestic and international. The Company has an extensive distribution network with three distribution centers located in Jakarta, Cikarang, and Surabaya, 48 branches across the Indonesian archipelago, and 23 branches through its subsidiary, PT Tri Sapta Jaya. To date, the Company has 10 subsidiaries operating in the distribution, raw materials, medical equipment, healthcare services, and transportation sectors.